Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01429155 · ClinicalTrials.gov registry record
Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 36
- Enrollment target
NCT01429155 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 36 participants.
The verdict
NCT01429155 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a national organ shortage, living donor liver transplantation has became a viable option for patients with end stage liver disease who are not severely ill. Recently particular polymorphisms of IL-28B gene were reported to correlate with histological recurrence and antiviral treatment response after orthotopic liver transplantation for hepatitis C. Similar results have not been described yet in living donor liver transplant patients. There is data suggesting slightly inferior outcomes in living donor liver transplants when done for hepatitis C. The investigators postulate that such inferior outcomes may be related to IL28 polymorphism concordance (i.e., unfavorable recipient polymorphism patients receive similarly unfavorable polymorphism livers from their relatives).
Interventions
- GENETIC Interleukin 28B genotype
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01429155
The ClinicalTrials.gov registry entry for NCT01429155 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interleukin 28B genotype is the first listed.
NCT01429155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01429155 about?
NCT01429155 is a clinical study titled "Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B". Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a national organ shortage, living donor liver transplantation has became a viable option for patients with end stage liver disease who are not severely ill. Recently particular polymorphisms of IL-28B gene were rep...
What is the current status of trial NCT01429155?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2011-08. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01429155?
The interventions under investigation include: Interleukin 28B genotype (GENETIC).
Who is sponsoring clinical trial NCT01429155?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.